Vyant Bio, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew D.C. LaFrence CPA
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 Executive Campus Cherry Hill NJ United States of America 08002
- IPO Date
- Apr 1, 2021
- CIK
- 0001349929
- Website
- vyantbio.com
- Similar Companies
- Business
- Vyant Bio, Inc. (VYNT) develops therapeutics for complex neurodevelopmental and neurodegenerative disorders through its central nervous system drug discovery platform, which integrates human-derived organoid models of brain disease, scaled biology, machine learning, and the proprietary AnalytiX platform for data analytics. The company offers microOrgan technology utilizing induced pluripotent stem cell-derived functional microtissues for high-throughput drug screening in formats such as multi-well plates, targeting rare genetic CNS conditions including Rett Syndrome with candidate VYNT-0126, CDKL5 deficiency disorders, and familial Parkinson's disease; it previously provided preclinical oncology and immuno-oncology services via subsidiary vivoPharm. Founded in 1999 and headquartered in Cherry Hill, New Jersey, Vyant Bio focuses on biopharma clients in neuroscience, oncology, and related fields across the United States. In recent developments, the company sold its vivoPharm U.S. operations to Reaction Biology in 2022 for approximately $4.4 million net cash to fund its CNS pipeline and divested StemoniX assets to AxoSim in 2023 for $2.25 million amid wind-down activities, with a Certificate of Dissolution filed in Delaware in December 2023.
Vyant Bio Provides Update on Winddown Activities
Vyant Bio Provides Update on Winddown Activities
Vyant Bio Announces Stockholder Approval of Plan of Dissolution
Vyant Bio Announces Completion of StemoniX Asset Sale
Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders
Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets
Vyant Bio to pursue listing on OTC Pink Open Market
Why Is Vyant Bio (VYNT) Stock Down 35% Today?
Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives
Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value
Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript
Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show
Vyant Bio showcases 'promise and potential' of its drug discovery platform at Boston medical conference
Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year